FDA Approves Gilead's Long-Acting HIV Prevention Injection
TL;DR Summary
The FDA has approved Gilead Sciences' twice-yearly injection, lenacapavir, for HIV prevention, showing over 99.9% effectiveness in clinical trials, which could be a major breakthrough in HIV prevention efforts, though concerns about high costs remain.
- Breakthrough: FDA Approves Injection to Prevent HIV ScienceAlert
- Regulators Approve Lenacapavir for H.I.V. Prevention The New York Times
- Gilead’s CEO on the approval of a powerful new drug to prevent HIV STAT
- HIV prevention drug hailed as a 'breakthrough' gets FDA approval : Goats and Soda NPR
- US FDA approves Gilead's twice-yearly injection for HIV prevention Reuters
Reading Insights
Total Reads
0
Unique Readers
0
Time Saved
3 min
vs 3 min read
Condensed
94%
546 → 35 words
Want the full story? Read the original article
Read on ScienceAlert